The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

A hypertension preload treatment formulation for limiting ingested sodium from entering the bloodstream and method of using the same. The hypertension preload treatment formulation is provided in an oral dosage from. The hypertension preload treatment formulation comprises a therapeutically effective dosage of a sodium-binding agent and an excipient. The sodium-binding agent is a resin comprising a polystyrene cross-linked chain structure formulated to sequestering sodium cations in the resin for later excretion. Methods of binding dietary sodium and treating or preventing hypernatremia in a hypertensive patient are also provided.

A hypertension preload treatment formulation for limiting ingested sodium from entering the bloodstream and method of using the same. The hypertension preload treatment formulation is provided in an oral dosage from. The hypertension preload treatment formulation comprises a therapeutically effective dosage of a sodium-binding agent and an excipient. The sodium-binding agent is a resin comprising a polystyrene cross-linked chain structure formulated to sequestering sodium cations in the resin for later excretion. Methods of binding dietary sodium and treating or preventing hypernatremia in a hypertensive patient are also provided.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.

The present disclosure relates to methods, compositions, and devices for treatments related to mammary tissue in subjects, including reducing the incidence of mastitis. In particular, the disclosure can relate to creating a physical barrier on a teat surface, in a teat canal, or in a teat cistern for prophylactic treatment of mammary disorders.

The present disclosure relates to methods, compositions, and devices for treatments related to mammary tissue in subjects, including reducing the incidence of mastitis. In particular, the disclosure can relate to creating a physical barrier on a teat surface, in a teat canal, or in a teat cistern for prophylactic treatment of mammary disorders.